Eli Lilly Spends $60M to Continue their Focus on Radiopharma Signal

By giving Aktis Oncology the initial payment of $60 million to develop medicinal and analytical treatments which aim at numerous targets, Eli Lilly keeps striving to capitalise on the radiopharma trend.

Lilly became involved in the emerging radiopharma industry late this past year when it paid $1.4 billion to acquire Point Biopharma. With the acquisition of a production facility, a research and development centre, and a pipeline focused on a radioligand treatment targeting PSMA, Lilly was able to establish a foundation for a larger initiative to integrate the method into its cancer pipeline.

Lilly expanded the scope of its growing radiopharma portfolio recently. Aktis accepted the remaining half of the bargain, committing to use its position to produce anticancer prospects directed against Lilly-selected choices. The deal has an initial value of $60 million and potential payments for milestones of up to $1.1 billion.